Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
TORL BioTherapeutics is a clinical-stage biopharmaceutical business.
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.
Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.
Ansa Biotechnologies develops a novel DNA synthesis technology based on enzymes.
IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.
ARS Pharmaceuticals is a stealth pharmaceutical company that specializes in developing anti allergy drugs.
PepGen is empowering nucleic acid therapeutics to go the distance.
KalVista Pharmaceuticals is an ophthalmology company focused on developing drugs for the treatment of diabetic macular edema (DME).
Metalex Commodities is a commodity trading company that specializes in the export of metal ores and concentrates.
Synapse Energy Economics is a consulting firm providing economic and policy analysis for the electric power sector.
Celcuity is a biotechnology company translating discoveries of new cancer sub-types into expanded therapeutic options for cancer patients.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.
Robotic microfactories for building net-zero homes 2x faster, 2x cheaper with 10x lower carbon
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.
Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.
Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.
Superluminal Medicines is a generative biological and chemical company that innovates drug discovery and development processes.
CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare .
Iterum Therapeutics is a clinical-stage pharmaceutical company that develops significantly differentiated anti-infectives.
Pahr Therapeutics is a clinical stage business, is to create innovative ways to treat pulmonary arterial hypertension.
Spyglass Pharma provides medicine for ophthalmic diseases.
Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.
Stylus Medicine is on a quest to create disease-treating agents for the next generation based on the groundbreaking work of its founders.
RA Capital Management has invested in 467 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Medical. The firm invests across 20 different industry categories.
Among tracked funding rounds, Avidity Biosciences received $690.0M in a Post Ipo Equity round. RA Capital Management's total known invested capital is $56.7B.
RA Capital Management's average investment size is $123.5M across its portfolio of 467 companies.
Recent RA Capital Management portfolio additions include TORL BioTherapeutics, Affinia Therapeutics, Star Therapeutics, Cidara Therapeutics, Ansa Biotechnologies. These companies were founded in 2020 or later.